Pfizer Pledges up to US$4.4 B for Myovant’s Orgovyx
By Sasha Yachu & Michelle Liu
Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)
Published: 15 Apr-2021
DOI: 10.3833/pdr.v2021.i4.2606 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Highlighting its commitment towards oncology and women’s health, Myovant Sciences has announced a collaboration with Pfizer to develop and commercialise OrgovyxTM (relugolix) in advanced prostate cancer in the US and Canada...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS